Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSab-NPs
- Development stage
- Preclinical
- Lead developer
- University of Tennessee Health Science Center
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
PSab-NPs is an experimental nanoparticle formulation of sabizabulin (VERU-111), a small molecule inhibitor that binds to the colchicine-binding site of tubulin. The formulation utilizes poly(lactic-co-glycolic acid) (PLGA) nanoparticles coated with poly-L-lysine (PLL) and stabilized by Pluronic F127 and polyvinyl alcohol (PVA). It is specifically designed to improve the therapeutic index of sabizabulin by enhancing bioavailability, facilitating tumor-specific accumulation, and evading lysosomal degradation through efficient endosomal release. Preclinical studies in cervical cancer models indicate that PSab-NPs inhibit microtubule dynamics, suppress the expression of HPV E6 and E7 oncoproteins, and modulate the PI3K/AKT/MDM2 signaling pathway, showing superior efficacy compared to the free drug.
- Other names
- Sabizabulin-loaded PLGA nanoparticlesPLL-coated Sabizabulin nanoparticles
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on PSab-NPs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSab-NPs.